A5079316525- Systemic Lupus Erythematosus Research
- Dermatology and Skin Diseases
- Dermatological and COVID-19 studies
- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Oral Health Pathology and Treatment
- Cytokine Signaling Pathways and Interactions
- Parvovirus B19 Infection Studies
- Chronic Lymphocytic Leukemia Research
- Genetic and rare skin diseases.
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Neonatal skin health care
- Otitis Media and Relapsing Polychondritis
- Asthma and respiratory diseases
- Contact Dermatitis and Allergies
- Allergic Rhinitis and Sensitization
- CNS Lymphoma Diagnosis and Treatment
- interferon and immune responses
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- IL-33, ST2, and ILC Pathways
Inserm
2021-2025
Assistance Publique – Hôpitaux de Paris
2017-2025
Hôpital Saint-Louis
2020-2025
Université Paris Cité
2021-2025
Délégation Paris 7
2025
Sorbonne Paris Cité
2025
Université Paris Nanterre
2023
Université Paris-Est Créteil
2023
Hôpitaux Universitaires Henri-Mondor
2023
University of London Institute in Paris
2022
Importance VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease caused by UBA1 somatic variants in hematopoietic progenitor cells, mostly involving adult men. It associated with inflammatory-related symptoms, frequently the skin and hematological disorders. Recently described myelodysplasia cutis (MDS-cutis) cutaneous manifestation of which clonal myelodysplastic cells infiltrate skin. In both cases, lesions are driven infiltration mutated myeloid...
Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin low-dose interferon had good overall response rates KS with acceptable tolerance profiles. addition, highlighted the aggressiveness compared a higher risk dissemination depletion as progression proceeded.
Cutaneous involvement of chronic graft-versus-host disease (cGVHD) has a wide range manifestations including lichenoid form with currently assumed mixed Th1/Th17 signature and sclerotic Th1 signature. Despite substantial heterogeneity innate adaptive immune cells recruited to the skin different clinical manifestations, treatment depends mainly on severity relies systemic, high-dose glucocorticoids alone or in combination calcineurin inhibitor. We performed first study using RNA sequencing...
Numerous network meta-analyses have provided comparative efficacy and safety data for treatments in psoriaasis over a short period (8-24 weeks). So, we conducted systematic review to map the design synthesize all 1-year of biologic moderate-to-severe psoriasis from randomized controlled trials (RCTs) included Cochrane (Sbidian et al., 2022). Among 81 RCTs included, many different designs are presented after induction phase. Within single trial, each arm (placebo, intervention, active...
To the Editor: We read, with great interest, studies by Kollman et al1Kollman N. Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully low-dose naltrexone.JAAD Case Rep. 2018; 4: 725-727Abstract Full Text PDF PubMed Scopus (15) Google Scholar and Alajmi al,2Alajmi A. Jfri Lovett Hailey-Hailey disease naltrexone magnesium.JAAD 2019; 5: 760-762Abstract (7) which reported efficacy of different dosages (LDN) in patients (HHD). Several have LDN HHD...